Catalyst Biosciences Inc (NASDAQ:CBIO)’s share price reached a new 52-week high on Friday . The stock traded as high as $19.19 and last traded at $18.63, with a volume of 840600 shares trading hands. The stock had previously closed at $17.15.
Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Tuesday, January 2nd. B. Riley set a $19.00 target price on shares of Catalyst Biosciences and gave the company a “buy” rating in a report on Monday, December 18th.
The company has a market cap of $112.38, a price-to-earnings ratio of -1.42 and a beta of 1.91.
A number of hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its stake in shares of Catalyst Biosciences by 117.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 173,555 shares of the biopharmaceutical company’s stock valued at $873,000 after purchasing an additional 93,592 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Catalyst Biosciences by 294.1% in the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 32,621 shares in the last quarter. Zacks Investment Management acquired a new stake in shares of Catalyst Biosciences in the 2nd quarter valued at about $147,000. Bank of New York Mellon Corp acquired a new stake in shares of Catalyst Biosciences in the 2nd quarter valued at about $107,000. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Catalyst Biosciences in the 2nd quarter valued at about $103,000. Hedge funds and other institutional investors own 22.96% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3146052/catalyst-biosciences-cbio-hits-new-1-year-high-at-19-19.html.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.